Clinical trial
An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL…
NCT00399048 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00399048 |
|---|---|
| Title | An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release) |
| Official title | A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Knee, Hip |
| Intervention type | Drug |
| Interventions | OROS hydromorphone HCL, OxyContin |
| Enrollment | 140 |
| Completion | May 1, 2001 |
| First posted | Nov 14, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: